DGAP-News

CEVEC raises EUR 4.5 million in a financing round to commercialize its leading CAP(R) based technologies - Seite 2

industrial production of viral vectors for gene therapy applications.
CAP(R)GT cells show a broad viral spectrum supporting lentiviral (LV),
adenoviral (AV) and adeno-associated viral (AAV) vectors. Growing in
serum-free suspension cultures, CAP(R)GT provides outstanding production
capabilities and high cell densities allowing for easier scale-up and
reduced production costs when compared to adherent cell culture systems.

"CAP(R)Go has the potential to become the new standard in glyco-optimized
protein production. Since its introduction, we are experiencing huge
interest in our unique expression system and were able to establish a
number of collaborations, the first with Biotest was announced in June,"
commented Frank Ubags, Chief Executive Officer of CEVEC Pharmaceuticals
GmbH. "One of the big challenges in gene therapy is the industrial
production of reliable and safe vectors that carry the DNA molecule to the
target cell. Our CAP(R)GT expression platform addresses this unmet need and
enables the commercial production of gene therapy treatments."

About CEVEC:

Privately held CEVEC, based in Cologne, Germany, is an expert for the
production of tailor-made recombinant glyco-proteins and gene therapy
vectors. The Company's core technologies, CAP(R)Go and CAP(R)GT are based
on a unique human cellular expression system.

The CAP(R)Go expression platform comprises a portfolio of glyco-optimized
human suspension cell lines for tailor-made glycosylation of recombinant
proteins. The cells are highly efficient for the production of a broad
range of difficult to express glycoproteins and provide authentic human
post-translational modifications. CAP(R)Go has proven to enhance the
activity, stability and serum half-life of several candidate proteins.

The CAP(R)GT expression platform provides a fully scalable, regulatory
endorsed production system for gene therapy vectors. CAP(R)GT cells grow to
high cell densities and show a broad viral propagation spectrum including
lentivirus (LV), adenovirus (AV) and adeno-associated virus (AAV).
Furthermore, CAP(R)GT enables easier scale-up and reduced production costs
when compared to adherent cell culture systems.

Research collaborations with international pharmaceutical and biotechnology
partners followed by licensing agreements for the technology form one
revenue base for CEVEC. In addition, the Company provides contract
manufacturing for the cGMP production in CAP(R)Go and CAP(R)GT cells.

In this financing round CEVEC was advised by Bergmann zur Hausen & Cie.
GmbH.


Contact:

CEVEC Pharmaceuticals GmbH                 MC Services AG
Frank Ubags                                Anne Hennecke
Chief Executive Officer                    Public Relations
T.:[phone]                        T.: [phone]
E.: [e-mail]                        E.: [e-mail]

www.cevec.com



---------------------------------------------------------------------

22.07.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


379853 22.07.2015